Our Diverse, Dedicated and Qualified Team

Odimma believes in the future of precision medicine, and leverages recent advances
in the field of immuno-oncology to fight the most difficult to target tumours.
Our complementary skills allow us to meet the challenges of an innovative personalised medicine.

Jean Marc Limacher, MD
Co-Founder, Chairman, CMO

Medical Oncologist & Cancer Geneticist

Pascale Balducchi, CEO
Partner, CBO

Strategy & Business Partnering

Pierre Marschall, PhD
Scientific Director


Rémi Gloeckler, PhD
Partner, Pharmaceutical Development


Jérémy Amzallag, Pharma D
Qualified Person


Célia Matta, PhD
Preclinical Researcher,
Head of Procurement


Cécile Hugel
Project Engineer

Biologist & Immunologist

Our Scientific & Medical Advisory Board

Jean-Yves Bonnefoy, PhD
President & CEO at Anagenesis Biotechnologies, France
Javier Cortés, MD
Head at International Breast Cancer Center, Spain
Prof. Pierre Coulie, MD, PhD
Head of Research Group at UCLouvain, Belgium
Prof. François Ghiringhelli, MD
Medical Oncologist at Centre Georges François Leclerc, France
Luca Gianni, MD
Head of Medical Oncology Department and Innovative Treatment at San Raffaele Cancer Center, Italy
Prof. Daniel Olive, MD, PhD
Head of Research Groups at Centre de Recherche en Cancérologie de Marseille, France
Olivia Pagani, MD
Coordinator of Breast Cancer Section at European School of Oncology, Switzerland
Prof. Solange Peters, MD
Chair Medical Oncology at CHUV Lausanne University, Switzerland
Prof. Robert Pirker, MD
Head at Medical University of Vienna, Austria
Ronald Rooke, PhD
Project Director at Servier, France
Prof. Egbert Smit, MD
Head of Thoracic Oncology Department at Netherlands Cancer Institute, Amsterdam
Patrick Squiban, MD
CEO of Health and Biotech France, France
Peter de Waele, PhD
Vice-President R&D and IP at Celyad, Belgium
Alejandro Yovine, MD
Global Clinical Head & Drug Development Oncology at Novartis, Switzerland